Lineage Cell Therapeutics (LCTX) Share-based Compensation (2010 - 2026)

Lineage Cell Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $40000.0 for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 166.67% year-over-year to $40000.0 in Q1 2026; TTM through Mar 2026 was -$1.2 million, a 129.55% decrease from a year earlier, with the FY2025 full-year figure at $6.2 million, down 24.39% from the prior year.
• Share-based Compensation improved to $40000.0 in Q1 2026 per LCTX's latest filing, from -$3.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $1.3 million in Q3 2024 and bottomed at -$3.6 million in Q4 2025.
• The 5-year median for Share-based Compensation is $1.2 million (2024), against an average of $756352.9.
• Across the five-year window, Share-based Compensation tumbled 376.65% in 2025 and jumped 166.67% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $959000.0 in 2022, then rose by 10.53% to $1.1 million in 2023, then climbed by 24.06% to $1.3 million in 2024, then tumbled by 376.65% to -$3.6 million in 2025, then jumped by 101.1% to $40000.0 in 2026.
• Per Business Quant, the three latest LCTX Share-based Compensation figures stand at $40000.0 (Q1 2026), -$3.6 million (Q4 2025), and $1.2 million (Q3 2025).